Sort
17,828 grants matching “crispr”
Molecular basis of action and pathogenesis of Clostridium difficile toxin B
$648,105Min Dong · Boston Children'S Hospital · R01 · FY2017 · AI
Impact of mutational order on molecular mechanisms of oncogenesis
$648,012Eirini Papapetrou · Icahn School Of Medicine At Mount Sinai · R01 · FY2025 · CA
Canonical to noncanonical Wnt signaling switch in airway epithelial health and disease
$647,973Eszter Katalin Vladar · University Of Colorado Denver · R01 · FY2024 · HL
Therapy Resistance Mechanisms for Cancer
$647,591Javed Khan · Division Of Basic Sciences - Nci · ZIA · FY2025 · CA
in vivo modeling of IgH-reprogrammed B cells in mice
$647,573James Even Voss · Scripps Research Institute, The · P01 · FY2025 · HL
HIV Viral Load Testing Using CRISPR Cascade Signal Amplification
$647,533Changchun Liu · University Of Connecticut Sch Of Med/Dnt · R01 · FY2025 · AI
Development of 3D Alveolar Tissue Models, CRISPR-editing and Microbiota-immune Response Assay Platforms for Deciphering Human Lung Immunity
$647,518Derya Unutmaz · Jackson Laboratory · U19 · FY2020 · AI
Using CRISPR technology to study the function of paralogous genes
$647,246Norbert Perrimon · Harvard Medical School · R24 · FY2018 · OD
Control of regulatory T cell fitness and function by heme synthesis
$647,187Xudong Li · Tufts University Boston · R01 · FY2025 · AI
MELT: Modulation of PSMA Expression for Lutetium Therapy
$647,080Thomas Hope · University Of California, San Francisco · R01 · FY2019 · CA
Biochemistry Core
$647,039Duck-Yeon Lee · National Heart, Lung, And Blood Institute · ZIC · FY2025 · HL
** AWARDS ISSUED PRIOR TO JANUARY 20, 2025, WERE FUNDED UNDER PREVIOUS ADMINISTRATIONS AND MAY NOT REFLECT THE PRIORITIES AND POLICIES OF THE CURRENT ADMINISTRATION.** HIDDEN HUNGER, A CONDITION THAT OCCURS WHEN INTAKE AND ABSORPTION OF ESSENTIAL MICRONUTRIENTS ARE TOO LOW TO MAINTAIN GOOD HEALTH, IS ONE OF THE MOST SERIOUS PROBLEMS WORLDWIDE. VITAMIN A IS AN ESSENTIAL MICRONUTRIENT THAT PLAYS CRUCIAL ROLES IN HUMAN HEALTH AND DEVELOPMENT. ITS DEFICIENCY IS ONE OF THE PREVAILING CAUSES OF BLINDNESS AND CHILD MORTALITY IN LOW-INCOME COUNTRIES WHERE MOST OF THE POPULATION MAINLY DEPENDS ON ONE TYPE OF STAPLES AS THE MAIN CALORIC SOURCE THAT IS NOT NECESSARILY RICH IN MICRONUTRIENTS. BIOFORTIFICATION OF CROPS PRESENTS A CHEAP, SUSTAINABLE, AND EASY-TO-ACCESS ALTERNATIVE TO COMBAT MICRONUTRIENT DEFICIENCIES. OVER THE LAST TWO DECADES EXTENSIVE EFFORTS HAVE BEEN TAKEN TO DEVELOP RICE VARIETIES ENRICHED WITH PROVITAMIN A. THESE EFFORTS HEAVILY RELIED ON GENETIC ENGINEERING TECHNIQUES SINCE CONVENTIONAL BREEDING IS NOT POSSIBLE AS PROVITAMIN A-RICH VARIANTS OF RICE DO NOT EXIST IN NATURE. TO DATE, TWO WELL-KNOWN GOLDEN RICE (GR) VARIETIES, NAMELY GR1 AND GR2, HAVE BEEN DEVELOPED. GR2 ACCUMULATES A HIGH LEVEL OF Β-CAROTENE, WHICH IS PROVITAMIN A. GR 2 HAS ALREADY RECEIVED FOOD SAFETY APPROVALS BY THE UNITED STATES, CANADA, AUSTRALIA, AND PHILIPPINES FOR COMMERCIAL FARMING TO MITIGATE VITAMIN A DEFICIENCY. ALTHOUGH GR2 CAN PROVIDE SIGNIFICANT PART OF THE DAILY REQUIRED AMOUNT OF VITAMIN A, IT SUFFERS FROM ISSUES THAT ADVERSELY AFFECT ITS NUTRITIONAL IMPACTS. THESE ISSUES INCLUDE STABLE ACCUMULATION AND STORAGE OF Β-CAROTENE, THE MAIN PROVITAMIN. THEREFORE, THE PURPOSE OF THIS WORK IS TO TACKLE THE SHORTCOMINGS OF EARLIER GENERATIONS OF GOLDEN RICE. THIS RESEARCH PROJECT IS TO ADDRESS THE USDA-NIFA-AFRI PROGRAM AREA 1B. FOUNDATIONAL KNOWLEDGE OF PLANT PRODUCTS (A1103), WHERE IT CALLS FOR STUDYING BIOSYNTHESIS OF PLANT-DERIVED, HIGH VALUE BIOMOLECULES FOR USE IN FOODS, PHARMACEUTICALS, AND OTHER PRODUCTS. THIS PROJECT AIMS TO MAINLY USE CRISPR GENOME ENGINEERING TOOLS TO ADDRESS THE SHORTCOMINGS OF GR2 BY EMPLOYING THREE DIFFERENT, YET PARALLEL, OBJECTIVES TO IMPROVE STORAGE, STABILITY, AND METABOLIC CONVERSION OF Β-CAROTENE IN THE RICE ENDOSPERM. FIRST, WE WILL IMPROVE Β-CAROTENE ACCUMULATION CAPACITY IN GR2 ENDOSPERM BY REGULATING CHROMOPLAST BIOGENESIS AND NUMBER. SECOND, WE WILL INCREASE Β-CAROTENE AVAILABILITY IN GR2 ENDOSPERM BY LIMITING ITS METABOLIC CONVERSION. THIRD, WE WILL ENHANCE POST-HARVEST STABILITY OF Β-CAROTENE IN GR2 SEEDS BY ALLEVIATING ITS DEGRADATION. THE PROPOSED RESEARCH WILL PROVIDE FOUNDATIONAL KNOWLEDGE ABOUT THE CAROTENOID METABOLISM IN RICE ENDOSPERM. FURTHERMORE, IT WILL AID THE ENGINEERING OF NEXT-GENERATION GOLDEN RICE 3 TO COMBAT GLOBAL VITAMIN A DEFICIENCY.
$647,000University Of Maryland, College Park · · FY2023 · National Institute of Food and Agriculture
In Vivo Base Editing for Precision Oncology Models
$646,960Lukas Edward Dow · Weill Medical Coll Of Cornell Univ · R01 · FY2019 · CA
A system approach to the analysis of Heterotaxy Candidate Genes
$646,936Mustafa K Khokha · Yale University · R01 · FY2020 · HD
Bladder cancer PD-L1 control of homologous recombination: Basic mechanisms applied to novel treatments
$646,659Tyler J. Curiel · Dartmouth-Hitchcock Clinic · R01 · FY2022 · CA
Deciphering molecular mechanisms controlling age-associated uterine adaptabilityto pregnancy
$646,628Xiaoqiu Wang · North Carolina State University Raleigh · R01 · FY2024 · HD
Protein aggregation in inclusion body and myofibrillar myopathies
$646,536Conrad C Weihl · Washington University · R01 · FY2024 · AG
Drug Screening with a Biofrabricated 3-D Immunocompetent Skin Model for Drug Discovery in Psoriatic Disease
$646,512Angela M Christiano · Columbia University Health Sciences · U18 · FY2020 · TR
Site-specific Integration of Large (10-100 kb) DNA Constructs into the Mouse Genome and Human Induced Pluripotent Stem Cells Using the Cas9-Bxb1 Integrase Toolbox
$646,321Vishnu Hosur · Jackson Laboratory · R01 · FY2022 · CA
A Comprehensive Resource for Manipulating the Drosophila Genome
$646,303Hugo J Bellen · Baylor College Of Medicine · R01 · FY2020 · GM
Systematic elucidation of endosomal trafficking as a therapeutic opportunity in AD using CRISPR-based functional genomics
$646,266Martin Kampmann · University Of California, San Francisco · R01 · FY2021 · AG
Systematic elucidation of endosomal trafficking as a therapeutic opportunity in AD using CRISPR-based functional genomics
$646,266Martin Kampmann · University Of California, San Francisco · R01 · FY2022 · AG
Ocular Gene Therapy
$646,258Zhijian Wu · National Eye Institute · ZIA · FY2019 · EY
Leveraging GWAS Findings to Map Variants and Identify Novel Effector Genes for Alcohol-Related Traits
$646,254Henry Richard Kranzler · University Of Pennsylvania · R01 · FY2023 · AA
Gene editing in the brain with CRISPR-PEG
$646,076Hye Young Lee · University Of Texas Hlth Science Center · R01 · FY2022 · MH